- ￥500 - 1360
- Solarbio
- 北京
- IE1070
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:-20℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:-20℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
Erlotinib
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
183321-74-6
- 规格：
1g/500mg/100mg
| 规格： | 1g | 产品价格： | ￥1360.0 |
|---|---|---|---|
| 规格： | 500mg | 产品价格： | ￥800.0 |
| 规格： | 100mg | 产品价格： | ￥500.0 |
| 基本信息 | |
| CAS | No.183321-74-6 |
| 中文名称 | 埃罗替尼 |
| 英文名称 | Erlotinib |
| 别名 | 埃罗替尼;NSC718781;OSI-744;R-1415;OSI744;CP-358774 |
| 分子式 | C22H23N3O4 |
| 分子量 | 393.44 |
| 溶解性 | Soluble in DMSO(Need ultrasonic) |
| 纯度 | ≥98% |
| 外观(性状) | White to yellow Solid |
| 储存条件 | Powder:-20℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| EC | EINECS 689-196-2 |
| MDL | MFCD08063588 |
| SMILES | C#CC1=CC=CC(NC2=NC=NC3=C2C=C(C(OCCOC)=C3)OCCOC)=C1 |
| InChIKey | AAKJLRGGTJKAMG-UHFFFAOYSA-N |
| InChI | InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25) |
| PubChem CID | 176870 |
| 靶点 | EGFR |
| 通路 | Angiogenesis;Protein Tyrosine Kinase/RTK; JAK/STAT Signaling |
| 背景说明 | Erlotinib是一种EGFR抑制剂。 |
| 生物活性 | Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor， with an IC50 of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer. Erlotinib is a click chemistry reagent， itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.[1-3] |
| In Vitro | Erlotinib (CP-358774) is also a potent inhibitor of the recombinant intracellular (kinase) domain of the EGFR， with an IC50 of 1 nM. The proliferation of DiFi cells is strongly inhibited by Erlotinib with an IC50 of 100 nM for an 8-day proliferation assay[1]. The combination of B-DIM and Erlotinib (2 μM) results in a significant inhibition of colony formation in BxPC-3 cells when compared with either agent alone. The combination of B-DIM and Erlotinib (2 μM) results in a significant induction of apoptosis only in BxPC-3 cells when compare with the apoptotic effect of either agent alone[2]. |
| 细胞实验 | Under the experimental conditions， the combination of B-DIM and Erlotinib (50 mg/kg， i.p.) treatment shows significant decrease (P [2]. Erlotinib (20 mg/kg， p.o.) significantly attenuates Cisplatin (CP)-induced body weight (BW) loss when compared to the CP+vehicle (V) rats[3] |
| 细胞实验 | To test the viability of cells treated with B-DIM， Erlotinib， or the combination， BxPC-3 and MIAPaCa cells are plated (3，000-5，000 per well) in a 96-well plate and incubated overnight at 37°C. A range of concentrations for both B-DIM (10-50 μM) and Erlotinib (1-5 μM) is initially tested. Based on the initial results， the concentration of B-DIM (20 μM) and Erlotinib (2 μM) are chosen for all assays. The effects of B-DIM (20 μM)， Erlotinib (2 μM)， and the combination on BxPC-3 and MIAPaCa cells are determined by the standard MTT assay after 72 h and is repeated three times. The color intensity is measured by a Tecan microplate fluorometer at 595 nm. DMSO-treated cells are considered to be the untreated control and assigned a value of 100%. In addition to the above assay， we have also done clonogenic assay for assessing the effects of treatment[2]. |
| 动物实验 | Mice[2] Female ICR-SCID (6-7 weeks old) mice are randomized into the following treatment groups (n=7): (a) untreated control; (b) only B-DIM (50 mg/kg body weight)， intragastric once every day; (c) Erlotinib (50 mg/kg body weight)， everyday i.p. for 15 days; and (d) B-DIM and Erlotinib， following schedule as for individual treatments. All mice are killed on day 3 following last dose of treatment， and their body weight is determined. One part of the tissue is rapidly frozen in liquid nitrogen and stored at ?70°C for future use and the other part is fixed in formalin and processed for paraffin block. H&E staining of fixed tissue section is used to confirm the presence of tumor(s) in each pancreas. Rats[3] Six-week-old male Sprague-Dawley (SD) rats weighing 180 to 210 g are used. Cisplatin (CP) is freshly prepared in saline at a concentration of 1 mg/mL and then injected intraperitoneally in SD rats (n=28) at a dose of 7 mg/kg on day 0. To investigate the effect of Erlotinib， 28 CP-N rats are divided into two groups. Separate groups (n=14) each of animals are administered with either Erlotinib (20 mg/kg) (CP+E， n=14) or vehicle (CP+V， n=14) daily by oral gavage from day -1 (24 hours prior to the CP injection) to day 3. Vehicle-treated groups receive an equivalent volume of saline. Five male SD rats at the age of 6 weeks are used as a normal control group (NC， n=5). The NC rats are given an equivalent volume of saline daily by oral gavage from day -1 to day 3. At day 4 (96 hours after CP injection)， each rat is anesthetized and sacrificed by exsanguination after the cardiac puncture; blood is collected by cardiac puncture and kidneys are collected. Renal tissue is divided; separate portions are snap-frozen in liquid nitrogen or fixed in 2% paraformaldehyde/phosphate-buffered saline (PBS) for later use. All surgery is performed under diethyl ether gas anesthesia， and all efforts are made to minimize suffering. |
| 激酶实验 | The kinase reaction is performed in 50 μL of 50 mM HEPES (pH 7.3)， containing 125 mM NaCl， 24 mM MgCl2， 0.1 mM Na3VO4， 20 μM ATP， 1.6 μg/mL EGF， and 15 ng of EGFR， affinity purified from A431 cell membranes. The compound in DMSO is added to give a final DMSO concentration of 2.5%. Phosphorylation is initiated by addition of ATP and proceeded for 8 mm at room temperature， with constant shaking. The kinase reaction is terminated by aspiration of the reaction mixture and is washed 4 times with wash buffer. Phosphorylated PGT is measured by 25 mim of incubation with 50 μL per well HRP-conjugated PY54 antiphosphotyrosine antibody， diluted to 0.2 μg/mL in blocking buffer (3% BSA and 0.05% Tween 20 in PBS). Antibody is removed by aspiration， and the plate is washed 4 times with wash buffer. The colonmetric signal is developed by addition of TMB Microwell Peroxidase Substrate， 50 μL per well， and stopped by the addition of 0.09 M sulfuric acid， 50μL per well. Phosphotyrosine is estimated by measurement of absorbance at 450 nm. The signal for controls is typically 0.6-1.2 absorbance units， with essentially no back ground in wells without AlP， EGFR， or POT and is proportional to the time of incubation for 10 mm[1]. |
| 数据来源文献 | [1]. Moyer JD， et al. Induction of apoptosis and cell cycle arrest by CP-358，774， an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997， 57(21)， 4838-4848. [2]. Ali S， et al. Apoptosis-inducing effect of erlotinib is potentiated by 3，3-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther， 2008， 7(6)， 1708-1719. [3]. Wada Y， et al. Epidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in rats. PLoS One. 2014 Nov 12;9(11):e111728. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
0008 血管生长素(Angiogenin) ELISA 48T/96T 2000/3000 进口分装 F0009 人血管生成素-2(Angiopoietin-2) ELISA 48T/96T 2000/3000 进口分装 F0010 人载脂蛋白E(APO E) ELISA 48T/96T 2000/3000 进口分装 F0011 人抗利尿激素(AVP) ELISA 48T/96T 2000/3000 进口分装 F0016 细胞凋亡相关
0008 血管生长素(Angiogenin) ELISA 48T/96T 2000/3000 进口分装 F0009 人血管生成素-2(Angiopoietin-2) ELISA 48T/96T 2000/3000 进口分装 F0010 人载脂蛋白E(APO E) ELISA 48T/96T 2000/3000 进口分装 F0011 人抗利尿激素(AVP) ELISA 48T/96T 2000/3000 进口分装 F0016 细胞凋亡相关
技术资料暂无技术资料 索取技术资料
IE1070 埃罗替尼 血管生成 索莱宝
￥500 - 1360
